Modulation by Syk of Bcl-2, calcium and the calpain-calpastatin proteolytic system in human breast cancer cells

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1833, Issue 10, 2013, Pages 2153-2164

  Fei, Bei ^a,b   Yu, Shuai ^a,b   Geahlen, Robert L ^a,b  

^a PURDUE UNIVERSITY   (United States)

^b Purdue University   (United States)

Author keywords

Bcl 2; Calpain; Calpastatin; NF B; PTP1B; Syk

Indexed keywords

CALCIUM; CALPAIN; CALPASTATIN; HYDROGEN PEROXIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN BCL 2; PROTEIN KINASE SYK; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BREAST CANCER; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CANCER CELL; CELL LYSATE; CONTROLLED STUDY; CYTOSOL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION;

BCL-2; CALPAIN; CALPASTATIN; NF-ΚB; PTP1B; SYK;

BLOTTING, WESTERN; BREAST NEOPLASMS; CALCIUM; CALCIUM-BINDING PROTEINS; CALPAIN; CELL ADHESION; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; HYDROGEN PEROXIDE; IMMUNOPRECIPITATION; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NF-KAPPA B; OXIDANTS; PHOSPHORYLATION; PROTEIN-TYROSINE KINASES; PROTEOLYSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; SUBCELLULAR FRACTIONS; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84879474571     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2013.05.010     Document Type: Article

References (75)

1. Geahlen R.L. Syk and pTyr'd: signaling through the B cell antigen receptor. Biochim. Biophys. Acta 2009, 1793:1115-1127.
2. Mócsai A., Ruland J., Tybulewicz V.L.J. The SYK tyrosine kinase: a crucial player in diverse biological functions. Nat. Rev. Immunol. 2010, 10:387-402.
3. Coopman P.J., Do M.T., Barth M., Bowden E.T., Hayes A.J., Basyuk E., Blancato J.K., Vezza P.R., McLeskey S.W., Mangeat P.H., Mueller S.C. The Syk tyrosine kinase suppresses malignant growth of human breast cancer cells. Nature 2000, 406:742-747.
4. Yanagi S., Inatome R., Takano T., Yamamura H. Syk expression and novel function in a wide variety of tissues. Biochem. Biophys. Res. Commun. 2001, 288:495-498.
5. Hoeller C., Thallinger C., Pratscher B., Bister M.D., Schicher N., Loewe R., Heere-Ress E., Roka F., Sexl V., Pehamberger H. The non-receptor-associated tyrosine kinase Syk is a regulator of metastatic behavior in human melanoma cells. J. Invest. Derm. 2005, 124:1293-1299.
6. Gibbins J., Asselin J., Farndale R., Barnes M., Law C.L., Watson S.P. Tyrosine phosphorylation of the Fc receptor gamma-chain in collagen-stimulated platelets. J. Biol. Chem. 1996, 271:18095-18099.
7. Miranti C.K., Leng L., Maschberger P., Brugge J.S., Shattil S.J. Identification of a novel integrin signaling pathway involving the kinase Syk and the guanine nucleotide exchange factor Vav1. Curr. Biol. 1998, 8:1289-1299.
8. Woodside D.G., Obergfell A., Leng L., Wilsbacher J.L., Miranti C.K., Brugge J.S., Shattil S.J., Ginsberg M.H. Activation of Syk protein tyrosine kinase through interaction with integrin beta cytoplasmic domains. Curr. Biol. 2001, 11:1799-1804.
9. Mocsai A., Abram C.L., Jakus Z., Hu Y., Lanier L.L., Lowell C.A. Integrin signaling in neutrophils and macrophages uses adaptors containing immunoreceptor tyrosine-based activation motifs. Nat. Immunol. 2006, 7:1326-1333.
10. Turner M., Mee P.J., Costello P.S., Williams O., Price A.A., Duddy L.P., Furlong M.T., Geahlen R.L., Tybulewicz V.L.J. Perinatal lethality and blocked B-cell development in mice lacking the tyrosine kinase Syk. Nature 1995, 378:298-302.
11. Cheng A.M., Rowley B., Pao W., Hayday A., Bolen J.B., Pawson T. Syk tyrosine kinase required for mouse viability and B-cell development. Nature 1995, 378:303-306.
12. Ulanova M., Puttagunta L., Marcet-Palacios M., Duszyk M., Steinhoff U., Duta F., Kim M.K., Indik Z.K., Schreiber A.D., Befus A.D. Syk tyrosine kinase participates in beta1-integrin signaling and inflammatory responses in airway epithelial cells. Am. J. Physiol. Lung Cell Mol. Physiol. 2005, 288:L497-L507.
13. Takada Y., Aggarwal B.B. TNF activates Syk protein tyrosine kinase leading to TNF-induced MAPK activation, NF-kappaB activation, and apoptosis. J. Immunol. 2004, 173:1066-1077.
14. Zhou Q., Geahlen R.L. The protein-tyrosine kinase Syk interacts with TRAF-interacting protein TRIP in breast epithelial cells. Oncogene 2009, 28:1348-1356.
15. Young R.M., Hardy I.R., Clarke R.L., Lundy N., Pine P., Turner B.C., Potter T.A., Refaeli Y. Mouse models of non-Hodgkin lymphoma reveal Syk as an important therapeutic target. Blood 2009, 113:2508-2516.
16. Hahn C.K., Berchuck J.E., Ross K.N., Kakoza R.M., Clauser K., Schinzel A.C., Ross L., Galinsky I., Davis T.N., Silver S.J., Root D.E., Stone R.M., DeAngelo D.J., Carroll M., Hahn W.C., Carr S.A., Golub T.R., Kung A.L., Stegmaier K. Proteomic and genetic approaches identify Syk as an AML target. Cancer Cell 2009, 16:281-294.
17. Buchner M., Fuchs S., Prinz G., Pfeifer D., Bartholome K., Burger M., Chevalier N., Vallat L., Timmer J., Gribben J.G., Jumaa H., Veelken H., Dierks C., Zirlik K. Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia. Cancer Res. 2009, 69:5424-5432.
18. Singh A., Greninger P., Rhodes D., Koopman L., Violette S., Bardeesy N., Settleman J. A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival. Cancer Cell 2009, 15:489-500.
19. Baudot A.D., Jeandel P.Y., Mouska X., Maurer U., Tartare-Deckert S., Raynaud S.D., Cassuto J.P., Ticchioni M., Deckert M. The tyrosine kinase Syk regulates the survival of chronic lymphocytic leukemia B cells through PKCδ and proteasome-dependent regulation of Mcl-1 expression. Oncogene 2009, 28:3261-3273.
20. Zhang J., Benavente C.A., McEvoy J., Flores-Otero J., Ding L., Chen X., Ulyanov A., Wu G., Wilson M., Wang J., Brennan R., Rusch M., Manning A.L., Ma J., Easton J., Shurtleff S., Mullighan C., Pounds S., Mukatira S., Gupta P., Neale G., Zhao D., Lu C., Fulton R.S., Fulton L.L., Hong X., Dooling D.J., Ochoa K., Naeve C., Dyson N.J., Mardis E.R., Bahrami A., Ellison D., Wilson R.K., Downing J.R., Dyer M.A. A novel retinoblastoma therapy from genomic and epigenetic analyses. Nature 2012, 481:329-334.
21. Minobe K., Onda M., Iida A., Kasumi F., Sakamoto G., Nakamura Y., Emi M. Allelic loss on chromosome 9q is associated with lymph node metastasis of primary breast cancer. Jpn. J. Cancer Res. 1998, 89:916-922.
22. Yuan Y., Mendez R., Sahin A., Dai J.L. Hypermethylation leads to silencing of the SYK gene in human breast cancer. Cancer Res. 2001, 61:5558-5561.
23. Sung Y.M., Xu X., Sun J., Mueller D., Sentissi K., Johnson P., Urbach E., Seillier-Moiseiwitsch F., Johnson M.D., Mueller S.C. Tumor suppressor function of Syk in human MCF10A in vitro and normal mouse mammary epithelium in vivo. PLoS One 2009, 4:e7445.
24. Dyss Z., Montcourrier P., Vidal B., Anguille C., Merezegue F., Sahuquet A., Mangeat P.H., Coopman P.J. The Syk tyrosine kinase localizes to the centrosomes and negatively affects mitotic progression. Cancer Res. 2005, 65:10872-10880.
25. Wang L., Devarajan E., He J., Reddy S.P., Dai J.L. Transcription repressor activity of spleen tyrosine kinase mediates breast tumor suppression. Cancer Res. 2005, 65:10289-10297.
26. Zhang X., Shrikhande U., Alicie B.M., Zhou Q., Geahlen R.L. Role of the protein tyrosine kinase Syk in regulating cell-cell adhesion and motility in breast cancer cells. Mol. Cancer Res. 2009, 7:634-644.
27. Lee W.J., Ma H., Takano E., Yang H.Q., Hatanaka M., Maki M. Molecular diversity in amino-terminal domains of human calpastatin by exon skipping. J. Biol. Chem. 1992, 267:8437-8442.
28. Parr T., Sensky P.L., Bardsley R.G., Buttery P.J. Calpastatin expression in porcine cardiac and skeletal muscle and partial gene structure. Arch. Biochem. Biophys. 2001, 395:1-13.
29. Cong M., Thompson V.F., Goll D.E., Antin P.B. The bovine calpastatin gene promoter and a new N-terminal region of the protein are targets for cAMP-dependent protein kinase activity. J. Biol. Chem. 1998, 273:660-666.
30. Takano J., Watanabe M., Hitomi K., Maki M. Four types of calpastatin isoforms with distinct amino-terminal sequences are specified by alternative first exons and differentially expressed in mouse tissues. J. Biochem. 2000, 128:83-92.
31. Rios-Doria J., Day K.C., Kuefer R., Rashid M.G., Chinnaiyan A.M., Rubin M.A., Day M.L. The role of calpain in the proteolytic cleavage of E-cadherin in prostate and mammary epithelial cells. J. Biol. Chem. 2003, 278:1372-1379.
32. Löfvenberg L., Backman L. Calpain-induced proteolysis of beta-spectrins. FEBS Lett. 1999, 443:89-92.
33. Cooray P., Yuan Y., Schoenwaelder S.M., Mitchell C.A., Salem H.H., Jackson S.P. Focal adhesion kinase (pp125FAK) cleavage and regulation by calpain. Biochem. J. 1996, 318:41-47.
34. Kishimoto A., Mikawa K., Hashimoto K., Yasuda I., Tanaka S., Tominaga M., Kuroda T., Nishizuka Y. Limited proteolysis of protein kinase C subspecies by calcium-dependent neutral protease (calpain). J. Biol. Chem. 1989, 264:4088-4092.
35. Frangioni J.V., Oda A., Smith M., Salzman E.W., Neel B.G. Calpain-catalyzed cleavage and subcellular relocation of protein phosphotyrosine phosphatase 1B (PTP-1B) in human platelets. EMBO J. 1993, 12:4843-4856.
36. Kuchay S.M., Kim N., Grunz E.A., Fay W.P., Chishti A.H. Double knockouts reveal that protein tyrosine phosphatase 1B is a physiological target of calpain-1 in platelets. Mol. Cell. Biol. 2007, 27:6038-6052.
37. Azarian S.M., King A.J., Hallett M.A., Williams D.S. Selective proteolysis of arrestin by calpain. J. Biol. Chem. 1995, 270:24375-24384.
38. Hirai S., Kawasaki H., Yaniv M., Suzuki K. Degradation of transcription factors, c-Jun and c-Fos, by calpain. FEBS Lett. 1991, 287:57-61.
39. Pariat M., Salvat C., Bebien M., Brockly F., Altieri E., Carillo S., Jariel-Encontre I., Piechaczyk M. The sensitivity of c-Jun and c-Fos proteins to calpains depends on conformational determinants of the monomers and not on formation of dimmers. Biochem. J. 2000, 345:129-138.
40. Kubbutat M.H., Vousden K.H. Proteolytic cleavage of human p53 by calpain: a potential regulator of protein stability. Mol. Cell. Biol. 1997, 17:460-468.
41. Shiraha H., Glading A., Chou J., Jia Z., Wells A. Activation of m-calpain (calpain II) by epidermal growth factor is limited by protein kinase A phosphorylation of m-calpain. Mol. Cell. Biol. 2002, 22:2716-2727.
42. Glading A., Bodnar R.J., Reynolds I.J., Shiraha H., Satish L., Potter D.A., Blair H.C., Wells A. Epidermal growth factor activates m-calpain (calpain II), at least in part, by extracellular signal-regulated kinase-mediated phosphorylation. Mol. Cell. Biol. 2004, 24:2499-2512.
43. Averna M., De Tullio R., Capini P., Salamino F., Pontremoli S., Melloni E. Changes in calpastatin localization and expression during calpain activation: a new mechanism for the regulation of intracellular Ca(2+)-dependent proteolysis. Cell. Mol. Life Sci. 2003, 60:2669-2678.
44. Tidball J.G., Spencer M.J. Calpains and muscular dystrophies. Int. J. Biochem. Cell Biol. 2000, 32:1-5.
45. Sandmann S., Yu M., Unger T. Transcriptional and translational regulation of calpain in the rat heart after myocardial infarction-effects of AT(1) and AT(2) receptor antagonists and ACE inhibitor. Br. J. Pharmacol. 2001, 132:767-777.
46. Tsuji T., Shimohama S., Kimura J., Shimizu K. m-Calpain (calcium-activated neutral proteinase) in Alzheimer's disease brains. Neurosci. Lett. 1998, 248:109-112.
47. Mamoune A., Luo J.-H., Lauffenburger D.A., Wells A. Calpain-2 as a target for limiting prostate cancer invasion. Cancer Res. 2003, 63:4632-4640.
48. Gonscherowski V., Becker B.F., Moroder L., Motrescu E., Gil-Parrado S., Gloe T., Keller M., Zahler S. Calpains: a physiological regulator of the endothelial barrier?. Am. J. Physiol. Heart Circ. Physiol. 2006, 290:H2035-H2042.
49. Maile L.A., Aday A.W., Busby W.H., Sanghani R., Veluvolu U., Clemmons D.R. Modulation of integrin antagonist signaling by ligand binding of the heparin-binding domain of vitronectin to the alphaVbeta3 integrin. J. Cell. Biochem. 2008, 105:437-446.
50. Ma H., Yankee T.M., Hu J., Asai D.J., Harrison M.L., Geahlen R.L. Visualization of Syk-antigen receptor interactions using green fluorescent protein: differential roles for Syk and Lyn in the regulation of receptor capping and internalization. J. Immunol. 2001, 166:1507-1516.
51. Tian L., Hires S.A., Mao T., Huber D., Chiappe M.E., Chalasani S.H., Petreanu L., Akerboom J., McKinney S.A., Schreiter E.R., Bargmann C.I., Jayaraman V., Svoboda K., Looger L.L. Imaging neural activity in worms, flies and mice with improved GCaMP calcium indicators. Nat. Methods 2009, 6:875-881.
52. Pellegatta F., Bertelli A.A., Staels B., Duhem C., Fulgenzi A., Ferrero M.E. Different short- and long-term effects of resveratrol on nuclear factor-kappaB phosphorylation and nuclear appearance in human endothelial cells. Am. J. Clin. Nutr. 2003, 77:1220-1228.
53. Bijli K.M., Fazal F., Minhajuddin M., Rahman A. Activation of Syk by protein kinase C-delta regulates thrombin-induced intercellular adhesion molecule-1 expression in endothelial cells via tyrosine phosphorylation of RelA/p65. J. Biol. Chem. 2008, 283:14674-14684.
54. Guttmann R.P., Elce J.S., Bell P.D., Isbell J.C., Johnson G.V. Oxidation inhibits substrate proteolysis by calpain I but not autolysis. J. Biol. Chem. 1997, 272:2005-2012.
55. Guttmann R.P., Johnson G.V. Oxidative stress inhibits calpain activity in situ. J. Biol. Chem. 1998, 273:13331-13338.
56. Lametsch R., Lonergan S., Huff-Lonergan E. Disulfide bond within mu-calpain active site inhibits activity and autolysis. Biochim. Biophys. Acta 2008, 1784:1215-1221.
57. Jang S.-H., Hwang S.A., Kim M., Yun S.-H., Kim M.-S., Karnik S.S., Lee C. A protein tyrosine phosphatase inhibitor, pervanadate, inhibits angiotensin II-induced β-arrestin cleavage. Mol. Cells 2009, 28:25-30.
58. Chen R., Valencia I., Zhong F., McColl K.S., Roderick H.L., Bootman M.D., Berridge M.J., Conway S.J., Holmes A.B., Mignery G.A., Velez P., Distelhorst C.W. Bcl-2 functionally interacts with inositol 1,4,5-trisphosphate receptors to regulate calcium release from the ER. J. Cell Biol. 2004, 166:193-203.
59. 2+-driven apoptosis in chronic lymphocytic leukemia cells by peptide-mediated disruption of Bcl-2-IP3 receptor interaction. Blood 2011, 117:2924-2934.
60. Cortesio C.L., Chan K.T., Perrin B.J., Burton N.O., Zhang S., Zhang Z.Y., Huttenlocher A. Calpain 2 and PTP1B function in a novel pathway with Src to regulate invadopodia dynamics and breast cancer cell invasion. J. Cell Biol. 2008, 180:957-971.
61. Averna M., de Tullio R., Passalacqua M., Slaamino F., Pontremoli S., Melloni E. Changes in intracellular calpastatin localization are mediated by reversible phosphorylation. Biochem. J. 2001, 354:25-30.
62. Rong Y.-P., Bultynck G., Aromolaran A.S., Zhong F., Parys J.B., De Smedt H., Mignery G.A., Roderick H.L., Bootman M.D., Distelhorst C.W. The BH4 domain of Bcl-2 inhibits ER calcium release and apoptosis by binding the regulatory and coupling domain of the IP3 receptor. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:14397-14402.
63. Schaecher K., Goust J.M., Banik N.L. The effects of calpain inhibition on IkB alpha degradation after activation of PBMCs: identification of the calpain cleavage sites. Neurochem. Res. 2004, 29:1443-1451.
64. Chen F., Demers L.M., Vallyathan V., Lu Y., Castranova V., Shi X. Impairment of NF-kappaB activation and modulation of gene expression by calpastatin. Am. J. Physiol. Cell Physiol. 2000, 279:C709-C716.
65. Han Y., Weinman S., Boldogh I., Walker R.K., Brasier A.R. Tumor necrosis factor-alpha-inducible IkappaBalpha proteolysis mediated by cytosolic m-calpain. A mechanism parallel to the ubiquitin-proteasome pathway for nuclear factor-kappab activation. J. Biol. Chem. 1999, 274:787-794.
66. Lin T.H., Rosales C., Mondal K., Bolen J.B., Haskill S., Juliano R.L. Integrin-mediated tyrosine phosphorylation and cytokine message induction in monocytic cells. A possible signaling role for the Syk tyrosine kinase. J. Biol. Chem. 1995, 270:16189-16197.
67. Obergfell A., Eto K., Mocsai A., Buensuceso C., Moores S.L., Brugge J.S., Lowell C.A., Shattil S.J. Coordinate interactions of Csk, Src, and Syk kinases with [alpha]IIb[beta]3 initiate integrin signaling to the cytoskeleton. J. Cell. Biol. 2002, 157:265-275.
68. Liu F., Sells M.A., Chernoff J. Protein tyrosine phosphatase 1B negatively regulates integrin signaling. Curr. Biol. 1998, 8:173-176.
69. Du X., Saido T.C., Tsubuki S., Indig F.E., Williams M.J., Ginsberg M.H. Calpain cleavage of the cytoplasmic domain of the integrin beta 3 subunit. J. Biol. Chem. 1995, 270:26146-26151.
70. Iliuk A.B., Martin V.A., Alicie B.M., Geahlen R.L., Tao W.A. In-depth analyses of kinase-dependent tyrosine phosphoproteomes based on metal ion-functionalized soluble nanopolymers. Mol. Cell. Proteomics 2010, 9:2162-2172.
71. Storr S.J., Mohammeda R.A.A., Woolston C.M., Green A.R., Parr T., Spiteri I., Caldas C., Ball G.R., Ellis I.O., Martin S.G. Calpastatin is associated with lymphovascular invasion in breast cancer. Breast 2011, 20:413-418.
72. Beckerle M.C., Burridge K., DeMartino G.N., Croall D.E. Colocalization of calcium-dependent protease II and one of its substrates at sites of cell adhesion. Cell 1987, 51:569-577.
73. Cuevas B.D., Abell A.N., Witowsky J.A., Yujiri T., Johnson N.L., Kesavan K., Ware M., Jones P.L., Weed S.A., DeBiasi R.L., Oka Y., Tyler K.L., Johnson G.L. MEKK1 regulates calpain-dependent proteolysis of focal adhesion proteins for rear-end detachment of migrating fibroblasts. EMBO J. 2003, 22:3346-3355.
74. Huttenlocher A., Palecek S.P., Lu Q., Zhang W., Mellgren R.L., Lauffenburger D.A., Ginsberg M.H., Horwitz A.F. Regulation of cell migration by the calcium-dependent protease calpain. J. Biol. Chem. 1997, 272:32719-32722.
75. Yuan Y., Liu H., Sahin A., Dai J.L. Reactivation of SYK expression by inhibition of DNA methylation suppresses breast cancer cell invasiveness. Int. J. Cancer 2005, 113:654-659.